Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
A Clinical Study Evaluating H1710 for Injection in Participants with Advanced Solid Tumors
Details : H1710 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2025
Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Orient EuroPharma
Deal Size : $11.2 million
Deal Type : Licensing Agreement
Details : Under the agreement, OncoVent agreed to grant exclusive rights to OEP, which will be responsible for the commercialization of MAb-B43.13 (oregovomab), an immunotherapy drug candidate, in Taiwan, including related regulatory applications and necessary cli...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 28, 2023
Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Orient EuroPharma
Deal Size : $11.2 million
Deal Type : Licensing Agreement
Reset All
